FTAI Aviation Ltd vs Zoetis Inc — how do they compare? FTAI Aviation Ltd trades at $169.8 (market cap $17.57B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and Zoetis Inc for 70 Days on average.
| FTAI | ZTS | |
|---|---|---|
Market Cap | $17.57B | $30.20B |
Volume | 1,905,014 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $310.04 | $147.53 |
52-Week Low | $152.80 | $69.09 |
Typical Hold Time | 23 Days | 70 Days |
Enterprise Value | $20.69B | $37.76B |
Dividend Yield | 1.17% | 2.9% |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.97, down 2.78% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong 2025 results with $2.51B revenue and $501M net income, though recent quarters missed EPS expectations. Recent developments include a $500M share repurchase program, acquisition of 27 Boeing aircraft, and expanded Asia-Pacific maintenance partnerships, signaling strategic growth initiatives.
FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target representing 89% upside. However, investors face risks from consecutive earnings misses, negative operating cash flow, and declining profit margins. The technical bearish trend and high valuation multiples (P/E 37.35, P/B 43.49) require careful monitoring of execution against growth expectations.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →